Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TST014
MIFTS: 46

Testicular Cancer

Categories: Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Testicular Cancer

About this section

MalaCards integrated aliases for Testicular Cancer:

Name: Testicular Cancer 12 36 54 42 15
Malignant Neoplasm of Testis 71 32
Testicular Carcinoma 54 17
Testicular Neoplasms 43 71
Testicular Malignant Germ Cell Tumor 71
Childhood Neoplasm of the Testis 12
Pediatric Testicular Neoplasm 12
Childhood Testicular Neoplasm 71
Carcinoma of the Testis 71
Testicular Neoplasm 17
Neoplasm of Testis 12
Testicular Tumors 15
Testicular Tumor 12
Testis Neoplasm 12
Testis Cancer 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2998
KEGG 36 H00023
ICD9CM 34 186
MeSH 43 D013736
SNOMED-CT 67 126900000 363449006
ICD10 32 C62 C62.9
UMLS 71 C0039590 C0153594 C0677483 more
Sources

Summaries for Testicular Cancer

About this section
MedlinePlus : 42 Testicles, or testes, make male hormones and sperm. They are two egg-shaped organs inside the scrotum, the loose sac of skin behind the penis. You can get cancer in one or both testicles. Testicular cancer mainly affects young men between the ages of 20 and 39. It is also more common in men who Have had abnormal testicle development Have had an undescended testicle Have a family history of the cancer Symptoms include pain, swelling, or lumps in your testicles or groin area. Doctors use a physical exam, lab tests, imaging tests, and a biopsy to diagnose testicular cancer. Most cases can be treated, especially if found early. Treatment options include surgery, radiation, and/or chemotherapy. Regular exams after treatment are important. Treatments may also cause infertility. If you may want children later on, you should consider sperm banking before treatment. NIH: National Cancer Institute

MalaCards based summary : Testicular Cancer, also known as malignant neoplasm of testis, is related to testicular seminoma and cryptorchidism, unilateral or bilateral. An important gene associated with Testicular Cancer is TDRG1 (Testis Development Related 1). The drugs Testosterone and Methyltestosterone have been mentioned in the context of this disorder. Affiliated tissues include testicles, testis and lymph node.

Disease Ontology : 12 A male reproductive system cancer that is located in the testicles.

KEGG : 36 Testicular germ cell tumor (TGCT) comprises about 98% of all testicular neoplasms and is thereby the most common malignancy among young males. Overall, three different entities of TGCT can be distinguished: teratomas and yolk sac tumors of newborns and infants, seminomatous and nonseminomatous germ cell tumors of adolescents and young adults, and spermatocytic seminoma of elderly men. Recent studies of TGCTs have suggested that overexpression of cyclin D2 is a very early, possibly the oncogenic, event in GC tumorigenesis.

Wikipedia : 74 Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system.... more...

Sources

Related Diseases for Testicular Cancer

About this section

Diseases related to Testicular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 testicular seminoma 33.2 CGB3 AFP
2 cryptorchidism, unilateral or bilateral 33.1 SHBG RXFP2 INSL3 CGB5 AFP
3 testicular disease 33.0 RXFP2 MIR199A1 INSL3 AFP
4 testicular leydig cell tumor 32.8 INSL3 CGB3
5 nonseminomatous germ cell tumor 32.0 CGB5 AFP
6 teratoma 31.9 CGB5 CGB3 AFP
7 germ cell cancer 31.5 MIR199A1 ALPP AFP
8 testicular germ cell tumor 31.3 STK11 CGB3 ALPP AFP
9 endodermal sinus tumor 31.3 MIR199A1 CGB3 AFP
10 seminoma 31.2 SSX2 MAGEA4 CGB5 CGB3 ALPP AFP
11 mixed germ cell tumor 31.0 CGB3 AFP
12 extragonadal germ cell cancer 31.0 CGB5 AFP
13 choriocarcinoma 30.9 CGB5 CGB3 ALPP
14 malignant teratoma 30.9 CGB5 AFP
15 chromosomal triplication 30.8 CGB3 AFP
16 testicular torsion 30.8 RXFP2 INSL3 CGB5
17 embryonal testis carcinoma 30.5 MIR199A1 AFP
18 gonadal germ cell tumor 30.5 CGB5 AFP
19 gonadoblastoma 30.3 CGB5 CGB3 ALPP
20 tuberculous epididymitis 30.3 CGB3 AFP
21 disorders of sexual development 30.3 SHBG RXFP2 INSL3 AFP
22 gonadal dysgenesis 30.2 SHBG CGB5 CGB3
23 spermatocytoma 30.2 SSX2 MAGEA4 AFP
24 germinoma 30.2 CGB5 CGB3 ALPP AFP
25 squamous cell carcinoma 29.5 STK11 MAGEA4 MAGEA1 CTAG1B BOK-AS1
26 esophageal cancer 29.2 XIST STK11 MIR199A1 MAGEA4 MAGEA1 ERCC1
27 rete testis neoplasm 12.4
28 embryonal carcinoma 11.7
29 testicular germ cell cancer 11.6
30 testis sarcoma 11.2
31 testis refractory cancer 11.2
32 spermatocele 11.2
33 sex cord-gonadal stromal tumor 11.2
34 testicular brenner tumor 11.2
35 gynandroblastoma 11.2
36 germ cells tumors 10.8
37 anorchia 10.6 RXFP2 INSL3 CGB5
38 mature teratoma 10.6
39 corpus luteum cyst 10.6 CGB5 AFP
40 infertility 10.5
41 in situ carcinoma 10.5
42 ectopic pregnancy 10.5 CGB5 CGB3 AFP
43 hypogonadism 10.5
44 brain germinoma 10.5 MAGEA4 AFP
45 microinvasive gastric cancer 10.5 XIST TDRG1 AFP
46 azoospermia 10.5
47 placenta disease 10.4 MIR199A1 CGB5 CGB3 AFP
48 sexual disorder 10.4
49 impotence 10.4
50 epidermoid cysts 10.4

Graphical network of the top 20 diseases related to Testicular Cancer:



Diseases related to Testicular Cancer
Sources

Symptoms & Phenotypes for Testicular Cancer

About this section
Sources

Drugs & Therapeutics for Testicular Cancer

About this section

Drugs for Testicular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
2
Methyltestosterone Approved Phase 4 58-18-4 6010
3
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
8
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
9 Androgens Phase 4
10 Follicle Stimulating Hormone Phase 4
11 Testosterone 17 beta-cypionate Phase 4
12 Estradiol 17 beta-cypionate Phase 4
13 Estradiol 3-benzoate Phase 4
14
Lenograstim Approved, Investigational Phase 3 135968-09-1
15
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
16
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
17
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
18
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
19
Ifosfamide Approved Phase 3 3778-73-2 3690
20
Etoposide Approved Phase 3 33419-42-0 36462
21
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
22
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
23
leucovorin Approved Phase 3 58-05-9 6006 143
24
Vinblastine Approved Phase 3 865-21-4 241903 13342
25
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
26
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
27
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
28
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
29
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
30
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
32 Anabolic Agents Phase 2, Phase 3
33 Cathartics Phase 2, Phase 3
34 Castor Phase 2, Phase 3
35 Laxatives Phase 2, Phase 3
36 Calcium, Dietary Phase 3
37 Immunologic Factors Phase 3
38 Tubulin Modulators Phase 3
39 Anti-Infective Agents Phase 3
40 Immunosuppressive Agents Phase 3
41 Antimetabolites Phase 3
42 Antimitotic Agents Phase 3
43 Etoposide phosphate Phase 3
44 Alkylating Agents Phase 3
45
Isophosphamide mustard Phase 3 0
46 Anti-Bacterial Agents Phase 3
47 Antibiotics, Antitubercular Phase 3
48 Antirheumatic Agents Phase 3
49 Dermatologic Agents Phase 3
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy Completed NCT01641172 Phase 4
2 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Completed NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
3 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
4 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
5 A Randomized Double-blind Study of Testosterone Replacement Therapy or Placebo in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency (Einstein-intervention) Completed NCT02991209 Phase 2, Phase 3 Testosterone;Placebos
6 Androgen Treatment in Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
7 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
8 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
9 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
10 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
11 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Active, not recruiting NCT01726374 Phase 3 BEP(500)
12 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
13 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
14 CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors Terminated NCT01014767 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Dactinomycin;Doxorubicin;Etoposide;Irinotecan;Leucovorin;Methotrexate;Temozolomide;Vincristine
15 Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
16 A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
17 Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT). Unknown status NCT01743482 Phase 2 Pazopanib
18 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
19 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
20 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
21 Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer Completed NCT03426865 Phase 2 Axumin PET scan
22 A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Completed NCT00183820 Phase 2 paclitaxel, gemcitabine, and oxaliplatin
23 A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor Completed NCT01684098 Phase 2 Tc 99m EC20
24 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
25 A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence Completed NCT00123773 Phase 2
26 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
27 A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer Completed NCT01242631 Phase 2 Everolimus
28 Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors Completed NCT02161692 Phase 2 Cyclophosphamide;Etoposide;Cisplatin;Bleomycin;Carboplatin
29 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
30 Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors Completed NCT00006043 Phase 2 temozolomide
31 Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors Completed NCT00003518 Phase 2 gemcitabine hydrochloride;paclitaxel
32 Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer. Completed NCT01466231 Phase 2 Everolimus
33 Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
34 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
35 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
36 High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
37 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
38 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
39 Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial. Completed NCT01851200 Phase 2 Brentuximab Vedotin
40 A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors Completed NCT00957905 Phase 2 Alvocidib Hydrochloride;Fluorouracil;Leucovorin Calcium;Oxaliplatin
41 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
42 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
43 Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease Completed NCT00463060 Phase 1, Phase 2 sunitinib malate (Sutent)
44 Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153 Completed NCT01736917 Phase 2 Fosaprepitant;Dexamethasone;5HT3
45 Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
46 Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
47 Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation Completed NCT00231582 Phase 2 epirubicin;paclitaxel;etoposide;ifosfamide;carboplatin
48 A Phase II Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor and Other Non-Carcinomas Completed NCT01277744 Phase 2 Cisplatin
49 A Biobehavioral Intervention for Young Men With Testicular Cancer: A Pilot Study Recruiting NCT04150848 Phase 2
50 Phase II Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer Recruiting NCT02860819 Phase 2 Veliparib;Gemcitabine;Carboplatin

Search NIH Clinical Center for Testicular Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Methotrexate
Methotrexate Sodium
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: testicular neoplasms

Sources

Genetic Tests for Testicular Cancer

About this section
Sources

Anatomical Context for Testicular Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Testicular Cancer:

19
Testicles

MalaCards organs/tissues related to Testicular Cancer:

40
Testis, Lymph Node, Testes, Prostate, Bone, Breast, Lung
Sources

Publications for Testicular Cancer

About this section

Articles related to Testicular Cancer:

(show top 50) (show all 6237)
# Title Authors PMID Year
1
Brain metastases from germ cell tumor: time to reconsider radiotherapy? 42
32353705 2020
2
Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. 42
32157202 2020
3
Primary testicular diffuse large B-cell lymphoma: Case series. 42
32195944 2020
4
Seminal expression of NY-ESO-1 and MAGE-A4 as markers for the testicular cancer. 54 61
19207618 2009
5
Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. 61 54
18440530 2009
6
Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. 54 61
18787014 2008
7
[Place of serum HCG assay in the follow-up of non-HCG-secreting testicular seminomas]. 61 54
18971108 2008
8
False tumor marker surge evoked by peripheral blood stem cell transplantation. 61 54
18515737 2008
9
Late relapse of testicular cancer 21 years after first complete remission: a case report. 54 61
18260359 2008
10
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. 61 54
16960727 2007
11
[Significance of thcg assay in the management of testicular cancer--the possibility of a standard assay in testicular cancer as an alternative to FbetahCG assay]. 61 54
17302291 2007
12
Immunostaining for placental alkaline phosphatase on fine-needle aspiration specimens to detect noninvasive testicular cancer: a prospective evaluation in cryptorchid men. 54 61
17227503 2007
13
Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. 54 61
16687567 2006
14
Y chromosome instability in testicular cancer. 61 54
16483836 2006
15
Immunostaining for placental alkaline phosphatase on fine-needle aspiration specimens to detect noninvasive testicular cancer: a prospective evaluation in cryptorchid men. 54 61
16643476 2006
16
[Two cases of testicular cancer with low human chorionic gonadotropin (hCG) levels after treatment]. 54 61
16119815 2005
17
Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer. 61 54
15885892 2005
18
Human tissue kallikrein gene family: applications in cancer. 61 54
15911097 2005
19
Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. 61 54
15685234 2005
20
Ethnic variation in the prevalence of AZF deletions in testicular cancer. 61 54
15450403 2004
21
Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer. 61 54
15242364 2004
22
Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. 54 61
15305826 2004
23
[Significance of current bio- and molecular-markers in urological cancers]. 54 61
15272577 2004
24
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. 61 54
14723995 2004
25
Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. 54 61
14668798 2003
26
[Paraneoplastic hyperthyroidism in a patient with metastasizing teratocarcinoma and excessively high HCG]. 61 54
14579189 2003
27
No AZF deletion in 160 patients with testicular germ cell neoplasia. 61 54
12900510 2003
28
E- and A-type cyclins as markers for cancer diagnosis and prognosis. 61 54
14510182 2003
29
[Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer]. 61 54
12910930 2003
30
Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. 61 54
12483540 2002
31
alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer. 61 54
11856111 2002
32
[Lung resistance protein analysis in testicular cancer]. 54 61
12563357 2002
33
[A prospect of molecular biology in the field of urologic oncology: mechanisms of carcinogenesis or tumor development in testicular cancer]. 54 61
11771175 2001
34
PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis. 61 54
11762823 2001
35
Organization and chromosomal localization of the murine Testisin gene encoding a serine protease temporally expressed during spermatogenesis. 61 54
11231276 2001
36
Localization, expression and genomic structure of the gene encoding the human serine protease testisin. 54 61
11004480 2000
37
Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans. 61 54
10408403 1999
38
125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. 61 54
10408402 1999
39
Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. 61 54
10071288 1999
40
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. 61 54
9887330 1999
41
Gonadotrophin secretion patterns in testicular cancer patients with greatly increased human chorionic gonadotrophin serum concentrations. 61 54
9834462 1998
42
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. 61 54
9823978 1998
43
Purification and characterization of alkaline phosphatase from human seminomas. 54 61
10359511 1998
44
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. 54 61
9605748 1998
45
Tumor markers in hydrocele fluids of patients with benign and malignant scrotal diseases. 54 61
9258097 1997
46
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. 54 61
8774142 1996
47
Immunological recognition and clinical significance of nicked human chorionic gonadotropin in testicular cancer. 61 54
7527309 1994
48
Human chorionic gonadotropin (hCG) and its free subunits in hydrocele fluids and neoplastic tissue of testicular cancer patients: insights into the in vivo hCG-secretion pattern. 61 54
7923124 1994
49
Role of human chorionic gonadotropin in patients with pure seminoma. 61 54
7525293 1994
50
Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. 54 61
8318413 1993
Sources

Variations for Testicular Cancer

About this section

Copy number variations for Testicular Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 61546 12 1 35400000 Gain Testicular cancer
2 202070 5 76900000 102800000 Loss Testicular cancer
3 217038 7 1 158821424 Gain Testicular cancer
4 237464 8 23300000 146274826 Gain Testicular cancer
5 262544 X 37500000 154913754 Gain Testicular cancer
6 262545 X 37500000 154913754 Gain Testicular cancer
7 266960 Y 174481503 174538309 Deletion AZF Testicular cancer
Sources

Expression for Testicular Cancer

About this section
Search GEO for disease gene expression data for Testicular Cancer.
Sources

Pathways for Testicular Cancer

About this section
Sources

GO Terms for Testicular Cancer

About this section

Biological processes related to Testicular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 female gamete generation GO:0007292 9.16 CGB5 CGB3
2 peptide hormone processing GO:0016486 8.96 CGB5 CGB3
3 hormone-mediated signaling pathway GO:0009755 8.8 RXFP2 CGB5 CGB3

Molecular functions related to Testicular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 INSL3 CGB5 CGB3
Sources

Sources for Testicular Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....